Canaccord Genuity Group Has Lowered Expectations for Artivion (NYSE:AORT) Stock Price

Artivion (NYSE:AORT) had its target price cut by investment analysts at Canaccord Genuity Group from $51.00 to $48.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 32.47% from the stock’s current price.

AORT has been the subject of a number of other reports. Wall Street Zen lowered shares of Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Oppenheimer reiterated an “outperform” rating and issued a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Finally, Citizens Jmp raised their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.69.

Artivion Trading Down 10.9%

Shares of Artivion stock opened at $36.24 on Friday. The company’s fifty day simple moving average is $43.60 and its 200-day simple moving average is $42.87. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. Artivion has a 1-year low of $21.97 and a 1-year high of $48.25. The stock has a market capitalization of $1.72 billion, a PE ratio of 181.18 and a beta of 1.59.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.74% and a net margin of 2.21%.The firm’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, equities analysts anticipate that Artivion will post 0.37 earnings per share for the current year.

Insiders Place Their Bets

In other Artivion news, SVP Marshall S. Stanton sold 47,376 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $45.04, for a total value of $2,133,815.04. Following the sale, the senior vice president directly owned 44,753 shares of the company’s stock, valued at approximately $2,015,675.12. This represents a 51.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider John E. Davis sold 6,394 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $45.17, for a total value of $288,816.98. Following the completion of the transaction, the insider directly owned 198,842 shares of the company’s stock, valued at $8,981,693.14. This trade represents a 3.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 128,448 shares of company stock worth $5,793,361. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently bought and sold shares of the company. Verition Fund Management LLC grew its holdings in Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after acquiring an additional 274 shares during the period. State of Alaska Department of Revenue increased its position in Artivion by 1.8% during the third quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after purchasing an additional 414 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Artivion by 6.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after purchasing an additional 477 shares in the last quarter. Arizona State Retirement System boosted its position in Artivion by 4.6% during the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after purchasing an additional 494 shares during the period. Finally, Van ECK Associates Corp raised its stake in shares of Artivion by 19.0% during the third quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock valued at $134,000 after purchasing an additional 506 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.